NASDAQ:ICVX Icosavax (ICVX) Stock Price, News & Analysis → Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (From Banyan Hill Publishing) (Ad) Free ICVX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$15.31▼$15.3150-Day Range$15.31▼$15.4552-Week Range$4.75▼$16.10VolumeN/AAverage Volume1.22 million shsMarket Capitalization$766.88 millionP/E RatioN/ADividend YieldN/APrice Target$26.50 Stock AnalysisStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial Media Get Icosavax alerts: Email Address Icosavax MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside73.1% Upside$26.50 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$229,350 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.20) to ($2.21) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.09 out of 5 starsMedical Sector777th out of 910 stocksBiotechnology Industry8th out of 15 stocks 3.2 Analyst's Opinion Consensus RatingIcosavax has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageIcosavax has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for ICVX. Previous Next 0.0 Dividend Strength Dividend YieldIcosavax does not currently pay a dividend.Dividend GrowthIcosavax does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ICVX. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Icosavax this week, compared to 1 article on an average week. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Icosavax insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $229,350.00 in company stock.Percentage Held by Insiders30.59% of the stock of Icosavax is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions92.59% of the stock of Icosavax is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Icosavax are expected to decrease in the coming year, from ($2.20) to ($2.21) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Icosavax is -6.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Icosavax is -6.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIcosavax has a P/B Ratio of 2.80. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingDon’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About Icosavax Stock (NASDAQ:ICVX)Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington. As of February 19, 2024, Icosavax, Inc. operates as a subsidiary of AstraZeneca PLC.Read More Ad Banyan Hill PublishingDon’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him ICVX Stock News HeadlinesApril 21, 2024 | morningstar.comNervGen Pharma Corp Ordinary Shares NGENApril 13, 2024 | americanbankingnews.comHead-To-Head Analysis: Icosavax (NASDAQ:ICVX) vs. Eupraxia Pharmaceuticals (OTCMKTS:EPRXF)April 23, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.March 20, 2024 | markets.businessinsider.comCHARM Therapeutics Announces Foundation of Scientific Advisory Board (SAB)February 11, 2024 | seekingalpha.comIcosavax: Tender Offer With Contingent Value RightJanuary 5, 2024 | seekingalpha.comIcosavax CVR Seems Fairly ValuedJanuary 2, 2024 | msn.comGuggenheim Downgrades Icosavax (ICVX)December 31, 2023 | businesswire.comICOSAVAX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Icosavax, Inc. - ICVXApril 23, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.December 24, 2023 | finance.yahoo.comChief Medical Officer Niranjan Kanesa-thasan Sells 11,884 Shares of Icosavax Inc (ICVX)December 18, 2023 | ca.finance.yahoo.comICVX Jul 2024 15.000 callDecember 16, 2023 | finance.yahoo.comInsider Sell Alert: Chief Business Officer Cassia Cearley Sells 8,759 Shares of Icosavax Inc (ICVX)December 13, 2023 | finance.yahoo.comIcosavax, Inc. (ICVX) Is Up 0.10% in One Week: What You Should KnowDecember 13, 2023 | finance.yahoo.comIcosavax, Inc. (ICVX) Moves to Buy: Rationale Behind the UpgradeDecember 12, 2023 | realmoney.thestreet.comIcosavax just downgraded at Jefferies, here's whyDecember 12, 2023 | msn.comIcosavax deal CVR based on FDA approval for IVX-A12, sales in EU, UK, CanadaDecember 12, 2023 | realmoney.thestreet.comIcosavax just downgraded at William Blair, here's whyDecember 12, 2023 | stockhouse.comShareholder Alert: Ademi LLP investigates whether Icosavax, Inc. has obtained a Fair Price in its transaction with AstraZenecaDecember 12, 2023 | tmcnet.comICVX STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Icosavax, Inc. Is Fair to ShareholdersDecember 12, 2023 | markets.businessinsider.comWhy Icosavax Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving PremarketDecember 12, 2023 | msn.comAstraZeneca to acquire vaccine maker Icosavax in ~$1.1B dealDecember 12, 2023 | finance.yahoo.comIcosavax Announces Positive Topline Interim Phase 2 Results for Combination VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older AdultsDecember 12, 2023 | finance.yahoo.comIcosavax, Inc. Announces Agreement to be Acquired by AstraZenecaDecember 8, 2023 | finance.yahoo.comWall Street Analysts Believe Icosavax, Inc. (ICVX) Could Rally 175.87%: Here's is How to TradeDecember 4, 2023 | finance.yahoo.comIcosavax, Inc. (ICVX) is on the Move, Here's Why the Trend Could be SustainableNovember 27, 2023 | msn.comIcosavax (ICVX) Price Target Increased by 5.00% to 24.99November 18, 2023 | msn.comGuggenheim Initiates Coverage of Icosavax (ICVX) with Buy RecommendationSee More Headlines Receive ICVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Icosavax and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today4/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:ICVX CUSIPN/A CIK1786255 Webicosavax.com Phone206-737-0085FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Stock Price Target$26.50 High Stock Price Target$28.00 Low Stock Price Target$25.00 Potential Upside/Downside+73.1%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-91,760,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-43.06% Return on Assets-39.53% Debt Debt-to-Equity RatioN/A Current Ratio18.06 Quick Ratio18.06 Sales & Book Value Annual Sales$580,000.00 Price / Sales1,322.20 Cash FlowN/A Price / Cash FlowN/A Book Value$5.47 per share Price / Book2.80Miscellaneous Outstanding Shares50,090,000Free Float34,767,000Market Cap$766.88 million OptionableOptionable Beta1.28 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Adam K. Simpson (Age 48)President, CEO, Co-Founder & Director Comp: $855.95kMr. Niranjan Kanesa-thasan M.D. (Age 63)Chief Medical Officer Comp: $641.55kDr. Cassia Cearley Ph.D. (Age 41)Treasurer & Chief Business Officer Comp: $632.15kMr. Neil King Ph.D.Chair of Scientific Advisory Board & Co-FounderDr. David Baker M.D.Ph.D., Co-founder & Member of Scientific Advisory BoardMr. Thomas Joseph Russo C.F.A. (Age 52)Chief Financial Officer Comp: $525.27kMs. Jennifer RaymondSenior Vice President of Technical OperationsMs. Elizabeth Bekiroglu (Age 54)General Counsel & Corporate Secretary Comp: $230.74kMs. Lori StewartSenior Vice President of People & CultureDr. Ami Shah Brown MPHPh.D., Senior Vice President of Regulatory AffairsMore ExecutivesKey CompetitorsGracell BiotechnologiesNASDAQ:GRCLDianthus TherapeuticsNASDAQ:DNTHWave Life SciencesNASDAQ:WVECogent BiosciencesNASDAQ:COGTStoke TherapeuticsNASDAQ:STOKView All CompetitorsInsiders & InstitutionsPlatinum Investment Management Ltd.Sold 955,374 shares on 2/14/2024Ownership: 2.756%Water Island Capital LLCBought 876,000 shares on 2/14/2024Ownership: 1.749%TIG Advisors LLCBought 507,122 shares on 2/14/2024Ownership: 1.012%Harvest Management LLCBought 79,000 shares on 2/14/2024Ownership: 0.158%PenderFund Capital Management Ltd.Bought 13,388 shares on 2/14/2024Ownership: 0.027%View All Insider TransactionsView All Institutional Transactions ICVX Stock Analysis - Frequently Asked Questions Should I buy or sell Icosavax stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Icosavax in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ICVX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ICVX, but not buy additional shares or sell existing shares. View ICVX analyst ratings or view top-rated stocks. What is Icosavax's stock price target for 2024? 3 brokers have issued 12 month price targets for Icosavax's stock. Their ICVX share price targets range from $25.00 to $28.00. On average, they anticipate the company's share price to reach $26.50 in the next year. This suggests a possible upside of 73.1% from the stock's current price. View analysts price targets for ICVX or view top-rated stocks among Wall Street analysts. How were Icosavax's earnings last quarter? Icosavax, Inc. (NASDAQ:ICVX) announced its quarterly earnings data on Monday, November, 15th. The company reported ($1.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by $0.81. The company earned $1.83 million during the quarter, compared to analyst estimates of $3.30 million. When did Icosavax IPO? Icosavax (ICVX) raised $150 million in an initial public offering on Thursday, July 29th 2021. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. This page (NASDAQ:ICVX) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishingtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders[Shocking] Elon Musk’s Plan To End BanksCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Icosavax, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
